Get the Stockscreener App
1.50
1.35%
0.02
After Hours:
1.60
0.10
+6.67%
In 8 Bio Inc stock is traded at $1.50, with a volume of 51,561.
It is up +1.35% in the last 24 hours and down -25.00% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.48
Open:
$1.55
24h Volume:
51,561
Relative Volume:
0.84
Market Cap:
$14.77M
Revenue:
-
Net Income/Loss:
$-19.44M
P/E Ratio:
-0.5642
EPS:
-2.6585
Net Cash Flow:
$-12.71M
1W Performance:
+7.14%
1M Performance:
-25.00%
6M Performance:
-27.88%
1Y Performance:
-71.35%
1-Day Range:
$1.48
$1.55
1-Week Range:
$1.3688
$1.59
52-Week Range:
$1.17
$5.817
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.50 | 14.57M | 0 | -19.44M | -12.71M | -2.6585 |
VRTX
Vertex Pharmaceuticals Inc
|
437.67 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.58 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
793.22 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.58 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.41 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Nasdaq warns BIO-key (NASDAQ: BKYI) after delayed 2025 Form 10-K - Stock Titan
Intelligent Bio Solutions (NASDAQ: INBS) posts new investor deck and share update - Stock Titan
Strategic review at Passage Bio (NASDAQ: PASG) after FDA trial guidance - Stock Titan
Rese-cel data expands across autoimmune diseases at Cabaletta Bio (CABA) - Stock Titan
Nasdaq warns Mustang Bio (MBIO) on sub-$1 share price and listing risk - Stock Titan
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Yahoo Finance
CyPath Lung case study at bioAffinity (NASDAQ: BIAF) shows biopsy deferred - Stock Titan
Ibtrozi Prospects Asserts Nuvation Bio Inc. (NUVB) as one of the Best Healthcare Penny Stocks - Yahoo Finance
Bio Green Med Solution, Inc. Files Form 8-K with SEC – Company Details, Nasdaq Listing, and Contact Information (April 2026) - Minichart
Boundless Bio, Inc. Files Form 8-K with SEC – Corporate Details, Nasdaq Listing, and Emerging Growth Company Status - Minichart
Boundless Bio (NASDAQ: BOLD) pays $10M to exit long-term lab lease - Stock Titan
Analysts Remain Bullish on Gossamer Bio (GOSS) Despite Phase 3 Setback - Insider Monkey
Gossamer Bio, Inc. 8-K SEC Filing April 2026 – NASDAQ Listing, Company Details, and Compliance Information - Minichart
Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Gossamer Bio Received Notice of Noncompliance - TradingView
Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan
Nasdaq warns Gossamer Bio (NASDAQ: GOSS) over sub-$1 share price - Stock Titan
ImmunityBio (NASDAQ: IBRX) Q1 revenue jumps 168% to $44.2M - Stock Titan
Primrose Bio Function Generator™ Combinatorial Genetic Technology Case Study Published in PNAS - Morningstar
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 - ChartMill
[ARS] Passage BIO, Inc. SEC Filing - Stock Titan
8 Most Oversold Penny Stocks to Buy Right Now - Insider Monkey
Adaptin Bio shares approved for OTCQB quotation under ticker APTN; trading to begin in 6-8 weeks - TradingView
Adaptin Bio (APTN) wins OTCQB quotation and advances APTN-101 program - Stock Titan
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Director Michael Hoffman buys 713,800 Annovis Bio (ANVS) shares in open market - Stock Titan
Entera Bio (NASDAQ: ENTX) completes private placement with BVF funds - Stock Titan
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Instil Bio (TIL) replaces Deloitte with RSM as independent auditor - Stock Titan
[144] Annovis Bio, Inc. SEC Filing - Stock Titan
Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan
GOSS SEC FilingsGossamer Bio 10-K, 10-Q, 8-K Forms - Stock Titan
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
APTN SEC FilingsAdaptin Bio 10-K, 10-Q, 8-K Forms - Stock Titan
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
FGEN SEC FilingsFibrogen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BIO SEC FilingsBio Rad Labs Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
ImmunityBio (NASDAQ: IBRX) adds $75M non-dilutive cash and converts $25M debt - stocktitan.net
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS
ACET SEC FilingsAdicet Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation - MSN
Vanguard reports zero beneficial holdings in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - stocktitan.net
Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
In 8 Bio Inc Stock (INAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McCall Patrick | CHIEF FINANCIAL OFFICER |
Apr 30 '25 |
Option Exercise |
0.18 |
15,000 |
2,766 |
67,071 |
| Roemer Alan S. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
113,459 |
20,922 |
398,489 |
| Brandt Peter C. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
163,934 |
30,229 |
681,538 |
2.53%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):